MannKind reported $110.9M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Adma Biologics USD 76.41M 6.8M Dec/2025
BioCryst Pharmaceuticals USD -553.84M 700.01M Mar/2026
Eli Lilly USD 10.02B 285M Mar/2026
Halozyme Therapeutics USD 192.19M 18.88M Mar/2026
Insmed USD 506.24M 7.31M Mar/2026
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025
MacroGenics USD 21.2M 32.13M Mar/2026
MannKind USD 110.9M 8.74M Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Novavax USD 126.2M 23.62M Dec/2025
Novo Nordisk DKK 6.5B 32.8B Jun/2025
Pfizer USD 90.1B 77.19B Mar/2026
Sanofi EUR 9.31B 1.2B Mar/2026
Xencor USD 82.38M 513K Mar/2026